| pubmed-article:16428940 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:16428940 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:16428940 | lifeskim:mentions | umls-concept:C0013227 | lld:lifeskim |
| pubmed-article:16428940 | lifeskim:mentions | umls-concept:C0278996 | lld:lifeskim |
| pubmed-article:16428940 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:16428940 | lifeskim:mentions | umls-concept:C0205420 | lld:lifeskim |
| pubmed-article:16428940 | lifeskim:mentions | umls-concept:C0599918 | lld:lifeskim |
| pubmed-article:16428940 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:16428940 | pubmed:dateCreated | 2006-1-23 | lld:pubmed |
| pubmed-article:16428940 | pubmed:abstractText | The goal of this study was to identify clinical characteristics and concurrent medications associated with an increased or decreased incidence of cisplatin-induced nephrotoxicity. The medical records for 62 subjects with head and neck cancer who received cisplatin 100 mg/m2 (day 1) plus fluorouracil 1000 mg/m2 (days 1-5) with or without radiation therapy were reviewed from three medical centers. The demographics, concurrent medication therapy, co-existing illnesses and clinical laboratory values were extracted from the medical records. Nephrotoxicity was defined as a minimum rise in serum creatinine of 0.5 mg/dl or above. The concurrent use of hydrochlorothiazide or multivitamins was associated with a higher incidence of nephrotoxicity after cycle 1. Use of albuterol, atenolol or hydrochlorothiazide was also associated with a higher incidence of nephrotoxicity after cycle 1 or 2. In contrast, subjects prescribed dexamethasone or ondansetron were less likely to experience nephrotoxicity. None of these medications affected treatment response. Race/ethnicity was independently correlated with the incidence of nephrotoxicity; African-American subjects were more likely to develop nephrotoxicity independent of the influence of these concurrent medications. Medications may modulate cisplatin-induced nephrotoxicity by altering the metabolic activation of cisplatin to a nephrotoxin. Genetic differences in the drug-metabolizing enzymes may contribute to the correlation with race. The results from this retrospective study provide data to support a larger prospective study to further investigate the associations between these concurrent medications and cisplatin-induced nephrotoxicity. | lld:pubmed |
| pubmed-article:16428940 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16428940 | pubmed:language | eng | lld:pubmed |
| pubmed-article:16428940 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16428940 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:16428940 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16428940 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16428940 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16428940 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16428940 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16428940 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16428940 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:16428940 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:16428940 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:16428940 | pubmed:issn | 0959-4973 | lld:pubmed |
| pubmed-article:16428940 | pubmed:author | pubmed-author:HaniganMarie... | lld:pubmed |
| pubmed-article:16428940 | pubmed:author | pubmed-author:ThompsonDavid... | lld:pubmed |
| pubmed-article:16428940 | pubmed:author | pubmed-author:ShordStacy... | lld:pubmed |
| pubmed-article:16428940 | pubmed:author | pubmed-author:KremplGreg... | lld:pubmed |
| pubmed-article:16428940 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:16428940 | pubmed:volume | 17 | lld:pubmed |
| pubmed-article:16428940 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:16428940 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:16428940 | pubmed:pagination | 207-15 | lld:pubmed |
| pubmed-article:16428940 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:16428940 | pubmed:meshHeading | pubmed-meshheading:16428940... | lld:pubmed |
| pubmed-article:16428940 | pubmed:meshHeading | pubmed-meshheading:16428940... | lld:pubmed |
| pubmed-article:16428940 | pubmed:meshHeading | pubmed-meshheading:16428940... | lld:pubmed |
| pubmed-article:16428940 | pubmed:meshHeading | pubmed-meshheading:16428940... | lld:pubmed |
| pubmed-article:16428940 | pubmed:meshHeading | pubmed-meshheading:16428940... | lld:pubmed |
| pubmed-article:16428940 | pubmed:meshHeading | pubmed-meshheading:16428940... | lld:pubmed |
| pubmed-article:16428940 | pubmed:meshHeading | pubmed-meshheading:16428940... | lld:pubmed |
| pubmed-article:16428940 | pubmed:meshHeading | pubmed-meshheading:16428940... | lld:pubmed |
| pubmed-article:16428940 | pubmed:meshHeading | pubmed-meshheading:16428940... | lld:pubmed |
| pubmed-article:16428940 | pubmed:meshHeading | pubmed-meshheading:16428940... | lld:pubmed |
| pubmed-article:16428940 | pubmed:meshHeading | pubmed-meshheading:16428940... | lld:pubmed |
| pubmed-article:16428940 | pubmed:meshHeading | pubmed-meshheading:16428940... | lld:pubmed |
| pubmed-article:16428940 | pubmed:meshHeading | pubmed-meshheading:16428940... | lld:pubmed |
| pubmed-article:16428940 | pubmed:meshHeading | pubmed-meshheading:16428940... | lld:pubmed |
| pubmed-article:16428940 | pubmed:meshHeading | pubmed-meshheading:16428940... | lld:pubmed |
| pubmed-article:16428940 | pubmed:meshHeading | pubmed-meshheading:16428940... | lld:pubmed |
| pubmed-article:16428940 | pubmed:meshHeading | pubmed-meshheading:16428940... | lld:pubmed |
| pubmed-article:16428940 | pubmed:year | 2006 | lld:pubmed |
| pubmed-article:16428940 | pubmed:articleTitle | Effect of concurrent medications on cisplatin-induced nephrotoxicity in patients with head and neck cancer. | lld:pubmed |
| pubmed-article:16428940 | pubmed:affiliation | Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Illinois, USA. | lld:pubmed |
| pubmed-article:16428940 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:16428940 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:16428940 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:16428940 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| pubmed-article:16428940 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16428940 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16428940 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:16428940 | lld:pubmed |
